Cmp Dev Llc patents expiration
1. Atorvaliq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11654106 | CMP DEV LLC | Aqueous suspension suitable for oral administration |
Jun, 2037
(13 years from now) | |
| US11369567 | CMP DEV LLC | Aqueous suspension suitable for oral administration |
Jun, 2037
(13 years from now) | |
Drugs and Companies using ATORVASTATIN CALCIUM ingredient
Market Authorisation Date: 01 February, 2023
Treatment: As an adjunct to other low-density lipoprotein cholesterol (ldl-c) lowering therapies, or alone if such treatments are unavailable, to reduce ldl-c in adults and pediatric patients aged 10 years and o...
Dosage: SUSPENSION;ORAL
ATORVALIQ family patents
2. Carospir patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11395828 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(12 years from now) | |
| US10660907 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(12 years from now) | |
| US10624906 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(12 years from now) | |
| US9757394 | CMP DEV LLC | Spironolactone aqueous formulations |
Oct, 2036
(12 years from now) | |
| US10888570 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(12 years from now) | |
| US11389461 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(12 years from now) | |
| US10493083 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(12 years from now) | |
| US11491166 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(12 years from now) | |
Drugs and Companies using SPIRONOLACTONE ingredient
Market Authorisation Date: 04 August, 2017
Treatment: Carospir is indicated for the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restriction; Carospir is indicated for treatment of nyha class iii-iv hea...
Dosage: SUSPENSION;ORAL
CAROSPIR family patents
3. Liqrev patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11337979 | CMP DEV LLC | Liquid oral formulations for sildenafil |
Dec, 2038
(14 years from now) | |
| US11464778 | CMP DEV LLC | Liquid oral formulations for sildenafil |
Dec, 2038
(14 years from now) | |
| US11759468 | CMP DEV LLC | Liquid oral formulations for sildenafil |
Dec, 2038
(14 years from now) | |
Drugs and Companies using SILDENAFIL CITRATE ingredient
Market Authorisation Date: 28 April, 2023
Treatment: Liqrev is indicated for the treatment of pulmonary arterial hypertension (who group 1) in adults to improve exercise ability and delay clinical worsening
Dosage: SUSPENSION;ORAL
LIQREV family patents
4. Norliqva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458095 | CMP DEV LLC | Pharmaceutical solution of amlodipine |
Feb, 2041
(16 years from now) | |
| US11253474 | CMP DEV LLC | Pharmaceutical solution of amlodipine |
Feb, 2041
(16 years from now) | |
| US11723866 | CMP DEV LLC | Pharmaceutical solution of amlodipine |
Feb, 2041
(16 years from now) | |
Drugs and Companies using AMLODIPINE BESYLATE ingredient
Market Authorisation Date: 24 February, 2022
Treatment: Norliqva is indicated for the treatment of confirmed or suspected vasospastic angina; Norliqva is indicated for the symptomatic treatment of chronic stable angina
Dosage: SOLUTION;ORAL
NORLIQVA family patents
5. Potassium Phosphates patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10632150 | CMP DEV LLC | Potassium phosphates composition for injection |
Apr, 2039
(14 years from now) | |
Drugs and Companies using POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC ingredient
Market Authorisation Date: 19 September, 2019
Treatment: Potassium phosphates injection is indicated as a source of phosphorus in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older
Dosage: SOLUTION;INTRAVENOUS
POTASSIUM PHOSPHATES family patents
6. Tadliq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11666576 | CMP DEV LLC | Liquid oral formulations for tadalafil |
Dec, 2038
(14 years from now) | |
| US11382917 | CMP DEV LLC | Liquid oral formulations for tadalafil |
Dec, 2038
(14 years from now) | |
Drugs and Companies using TADALAFIL ingredient
Market Authorisation Date: 17 June, 2022
Treatment: Tadliq is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability
Dosage: SUSPENSION;ORAL
TADLIQ family patents